Last updated: July 24, 2026
Forest Laboratories LLC v. Apotex Corp. | 1:15-cv-00018: Litigation Summary, Patent Issues, and Generic Risk Outlook
Forest Laboratories LLC sued Apotex Corp. in 2015 in U.S. federal court over generic entry aligned to an Orange Book-listed patent estate tied to Forest’s branded drug. The docket is indexed as Forest Laboratories LLC v. Apotex Corp., case number 1:15-cv-00018. The available prompt data does not include the court, asserted patent numbers, claims, settlements, or final disposition, so a complete, accurate litigation breakdown cannot be produced.
Result: No litigation summary, patent-issue analysis, or generic-entry timing assessment can be provided from the information supplied.
What is the Forest Laboratories LLC v. Apotex Corp. 1:15-cv-00018 litigation about?
A litigation summary requires the complaint and docket entries showing:
- asserted Orange Book patent(s) and claim(s)
- the FDA drug reference and listed NDA/BLA
- the Paragraph IV theory (infringement and invalidity grounds)
- the court/jurisdiction and procedural posture
None of those fields are present in the provided material.
Which patents were asserted in Forest Laboratories LLC v. Apotex Corp. 1:15-cv-00018?
A reliable patent identification requires at minimum:
- patent numbers listed in the complaint and/or the cited Orange Book patents in the notice of statutory basis
- relevant method-of-use, formulation, and/or composition-of-matter patents
- prosecution histories or claim construction orders (if issued)
No patent numbers are provided.
What claims did Apotex challenge under the Paragraph IV framework?
A Paragraph IV litigation analysis requires:
- the specific invalidity theories (35 USC 102/103/112, obviousness-type double patenting, nonstatutory obviousness, etc.)
- claim construction outcomes affecting infringement determinations
- the “no infringement” positions for each asserted claim
None of those details are included.
How did the court rule in Forest Laboratories LLC v. Apotex Corp. 1:15-cv-00018?
A disposition summary requires:
- motions to dismiss or transfer outcomes
- summary judgment rulings
- claim construction orders (often decisive)
- injunction or stipulation terms if a settlement occurred
No rulings or orders are included.
Did Forest and Apotex reach a settlement, and what were the effective dates?
Settlement analysis depends on:
- whether there was a consent judgment
- the design-around or carve-outs
- launch-date “trigger” provisions
- stipulated dismissal terms and any confidentiality-redacted agreement dates
No settlement terms or effective dates are provided.
What is the FDA/Orange Book exclusivity timeline tied to this case?
Timeline assessment requires:
- the NDA number and listed patents
- expiration dates (including PTA, pediatric exclusivity, exclusivity extensions)
- potential 180-day exclusivity status if applicable
- whether Apotex was first filer or later filer
The prompt provides no FDA/Orange Book linkage.
What generic launch risks exist for the drug implicated in 1:15-cv-00018?
Generic risk depends on:
- whether asserted patents were invalidated or found not infringed
- ongoing appeals or remaining asserted patents
- any continuing injunction during appeal
- whether non-asserted patents still block launch
No asserted-patent set or remaining estates are available.
Which companies are competing on the same Orange Book patent estate?
A competitor map requires:
- all Paragraph IV filers listed against the same NDA and patents
- subsequent litigation by other applicants
- any group settlement dynamics
No such dataset is included.
How does Forest’s patent estate compare with Apotex’s design-around?
This requires:
- the formulation or method-of-use at issue
- any claim chart evidence in the record
- the generic product profile and labeling paragraphs submitted to FDA
No product- or design-around details are provided.
How many related cases involved Forest and Apotex around 2015 for the same product?
A related-case count requires:
- searching dockets for co-pending matters
- identifying identical asserted patents and NDA numbers
- tracking consolidated or coordinated proceedings
No related-case pointers are provided.
Key Takeaways
- Case number: 1:15-cv-00018 (Forest Laboratories LLC v. Apotex Corp.).
- The supplied information does not include the operative complaint, asserted patents, procedural history, rulings, settlement terms, or FDA/Orange Book linkage.
- A litigation summary and patent-risk analysis cannot be generated from the provided inputs.
FAQs
- What is the Orange Book listing associated with Forest Laboratories LLC v. Apotex Corp. 1:15-cv-00018?
- Which Paragraph IV patents were asserted in this case?
- Did the court issue claim construction orders affecting infringement?
- Was there a settlement that delayed generic launch, and what were the trigger dates?
- Are there ongoing appeals or parallel cases tied to the same asserted patent estate?
References
- (No citable sources provided in the prompt.)
